Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
XBIO | US
0.23
7.59%
Healthcare
Biotechnology
30/06/2024
20/03/2026
3.26
3.02
3.26
2.96
Xenetic Biosciences Inc. a biopharmaceutical company focuses on advancing XCART a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition the company leveraging PolyXen its proprietary drug delivery platform by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd. Serum Institute of India Limited and PJSC Pharmsynthez. Xenetic Biosciences Inc. is headquartered in Framingham Massachusetts.
View LessPositive Momentum
Strength based on increasing price with high volume
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
132.5%1 month
107.3%3 months
87.1%6 months
226.0%-
-
0.79
-
-
1.03
0.12
-
-5.75M
5.03M
5.03M
-
-184.11
-
11.60
-48.61
0.20
0.21
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.29
Range1M
1.29
Range3M
1.54
Rel. volume
1.23
Price X volume
110.53K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ADTX | ADTX | Biotechnology | 1.3 | 5.49M | 4.00% | n/a | 122.46% |
| Alaunos Therapeutics Inc | TCRT | Biotechnology | 3.22 | 5.16M | n/a | 0.00% | |
| Genprex Inc | GNPX | Biotechnology | 1.88 | 4.87M | -2.08% | n/a | 0.00% |
| Evogene Ltd | EVGN | Biotechnology | 0.846 | 4.73M | -0.09% | n/a | 26.41% |
| Curis Inc | CRIS | Biotechnology | 0.7712 | 4.61M | 1.89% | n/a | -6039.91% |
| Brainstorm Cell Therapeutics Inc | BCLI | Biotechnology | 0.843 | 4.48M | n/a | -27.28% | |
| Enzon Pharmaceuticals Inc | ENZN | Biotechnology | 0.06 | 4.28M | 12.00 | 0.00% | |
| Immuron Limited | IMRN | Biotechnology | 0.703 | 4.27M | -0.85% | n/a | 1.37% |
| SNTI | SNTI | Biotechnology | 0.92 | 4.21M | 2.14% | n/a | 80.96% |
| BioCardia Inc | BCDA | Biotechnology | 1.2 | 4.20M | 0.00% | n/a | -58.03% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.3938 | 3.75M | 0.31% | n/a | 19.98% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.23 | 3.14M | n/a | 17.32% | |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.09 | 1.15M | -2.34% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.03 | - | Expensive |
| Ent. to Revenue | 0.12 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.79 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 87.06 | - | Par |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 5.03M | - | Emerging |